Study Summary
The primary objective of this study is to evaluate the safety and clinical activity of anti-CD19 Chimeric Antigen Receptor T cells (KD-019 CAR-T)infusion in the treatment of relapsed/refractory B-cell Lymphoma and B-cell acute lymphoblastic leukemia （B-ALL）.
Interested in this trial?
Submit an InquiryInterventions
Anti-CD19 CAR-T Cells InjectionBIOLOGICAL
Autologous genetically modified anti-CD19 CAR transduced T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Kunming Yan'an Hospital, Oncology Department | Kunming | Yunnan | China |